ERBB2 and breast carcinoma: In HER2-positive breast cancer patients, 33 of 85 plasma metabolome levels were significantly altered 2 weeks after completion of doxorubicin treatment, when compared to those of baseline (Table 1; Additional file 1: Table S4).